Safety and efficacy of balloon‐occluded transcatheter arterial chemoembolization using miriplatin for hepatocellular carcinoma

Publisher： John Wiley & Sons Inc

E-ISSN： 1872-034x|45|6|663-666

ISSN： 1386-6346

Source： HEPATOLOGY RESEARCH, Vol.45, Iss.6, 2015-06, pp. : 663-666

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Balloon-Occluded Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma: A Single-Center Experience

By  

Oncology, Vol. 89, Iss. 2, 2015-0 ,pp. : 27-32

Karger

Access to resources Recommend Favorite

Efficacy and safety of cisplatin versus miriplatin in transcatheter arterial chemoembolization and transarterial infusion chemotherapy for hepatocellular carcinoma: A randomized controlled trial

By  

HEPATOLOGY RESEARCH, Vol. 45, Iss. 5, 2015-05 ,pp. : 514-522

John Wiley & Sons Inc

Access to resources Recommend Favorite

Factors predicting overall response and overall survival in hepatocellular carcinoma patients undergoing balloon‐occluded transcatheter arterial chemoembolization: A retrospective cohort study

By  

HEPATOLOGY RESEARCH, Vol. 48, Iss. 2, 2018-02 ,pp. : 165-175

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prospective, randomized, controlled study of the efficacy of transcatheter arterial chemoembolization with miriplatin for hepatocellular carcinoma

By  

HEPATOLOGY RESEARCH, Vol. 48, Iss. 3, 2018-02 ,pp. : E98-E106

John Wiley & Sons Inc

Access to resources Recommend Favorite

Previous Chemoembolization Response after Transcatheter Arterial Chemoembolization (TACE) Can Predict the Anti-Tumor Effect of Subsequent TACE with Miriplatin in Patients with Recurrent Hepatocellular Carcinoma

By  

Oncology, Vol. 80, Iss. 3-4, 2011-06 ,pp. : 188-194

Karger

Access to resources Recommend Favorite